Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery
Yasufumi Kuroda,1 Chie Hirayama,2 Hitoshi Hotoda,2 Yasuhiro Nishikawa,2 Akinori Nishiwaki21Daiichi Sankyo Pharma Development, Edison, NJ, USA; 2Daiichi Sankyo Company, Limited, Tokyo, JapanPurpose: Edoxaban is an oral, once-daily, selective, direct factor Xa inhibitor approved in Japan for the preve...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-10-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | http://www.dovepress.com/postmarketing-safety-experience-with-edoxaban-in-japan-for-thromboprop-a14606 |